Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cleary, S. P.
Right arrow Articles by Gryfe, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleary, S. P.
Right arrow Articles by Gryfe, R.
[Cancer Research 63, 1769-1771, April 15, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

Heterozygosity for the BLMAsh Mutation and Cancer Risk1

Sean P. Cleary, William Zhang, Nando Di Nicola, Melyssa Aronson, Jennifer Aube, Amanda Steinman, Riad Haddad, Mark Redston, Steven Gallinger, Steven A. Narod and Robert Gryfe2

Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital [S. P. C., N. D., A. S., R. H., S. G., R. G.], Department of Surgery [S. P. C., M. A., R. H., S. G., R. G.], Centre for Research in Women’s Health, Sunnybrook and Women’s College Health Sciences Centre [W. Z., J. A., S. A. N.], University of Toronto, Toronto, Ontario, M5G 1X5, Canada, and Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts [M. R.]

Bloom syndrome is an autosomal recessive disorder whose characteristics include an increased risk for many types of cancers. In contrast to the homozygous mutations of Bloom syndrome, heterozygous carriers of BLM mutations may be at increased risk for developing colorectal cancer. We have screened 2,333 Jewish individuals, including 497 individuals with colorectal cancer, 125 with adenomatous polyps, 767 with noncolorectal cancers and 944 controls for the truncating BLMAsh founder mutation. The BLMAsh mutation was carried by 0.80% of individuals with colorectal neoplasia, 0.87% of those with any type of cancer and 0.85% of controls. In addition to case-control data, we found no evidence to support a significant relationship between increased cancer risk and heterozygous BLMAsh mutations with respect to age of cancer diagnosis, tumor multiplicity or family cancer history.




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
Z. Kemp, C. Thirlwell, O. Sieber, A. Silver, and I. Tomlinson
An update on the genetics of colorectal cancer
Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R177 - R185.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.